Randomized phase II trial of the neurokinin-1 receptor antagonist (NK-1 RA) casopitant mesylate with ondansetron (ond)/dexamethasone (dex) for chemotherapy-induced nausea/vomiting (CINV) in patients (pts) receiving highly emetogenic chemotherapy (HEC).

被引：0
|
作者：
Rolski, J.
Ramlau, R.
Dediu, M.
Russo, M. W.
Ross, G. A.
Mather, R. A.
Bandekar, R. R.
Grunberg, S. M.
机构：
[1] Oncol Ctr, Krakow, Poland
[2] Reg Lung Dis Ctr, Poznan, Poland
[3] Inst Oncol, Bucharest, Romania
[4] GlaxoSmithKline Inc, Collegeville, PA USA
[5] Univ Vermont, Burlington, VT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8513
引用
收藏
页码：471S / 471S
页数：1
相关论文
共 50 条
  • [31] Dolasetron (DOL) vs ondansetron (OND) with and without dexamethasone (DEX) in the prevention of nausea (N) and vomiting (V) in patients (PTS) receiving moderately emetogenic chemotherapy (MEG)
    Lofters, WS
    Zee, B
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 1205 - 1205
  • [32] Palonosetron (PALO) versus granisetron (GRA) in the triplet regimen with dexamethasone (DEX) and aprepitant (APR) for preventing chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving highly emetogenic chemotherapy (HEC) with cisplatin (CDDP): A randomized, double-blind, phase III trial.
    Hashimoto, Hironobu
    Yamanaka, Takeharu
    Shimada, Yasuhiro
    Arata, Koji
    Matsui, Reiko
    Goto, Koichi
    Takiguchi, Tomomi
    Ohyanagi, Fumiyoshi
    Kogure, Yuki
    Nogami, Naoyuki
    Nakao, Masahiko
    Takeda, Koji
    Azuma, Kanako
    Nagase, Seisuke
    Hayashi, Toshinobu
    Fujiwara, Kimiko
    Shimada, Toshikazu
    Seki, Nobuhiko
    Suzuki, Kenichi
    Yamamoto, Nobuyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [33] A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy
    Yeo, Winnie
    Mo, F. K. F.
    Suen, J. J. S.
    Ho, W. M.
    Chan, S. L.
    Lau, W.
    Koh, J.
    Yeung, W. K.
    Kwan, W. H.
    Lee, K. K. C.
    Mok, T. S. K.
    Poon, A. N. Y.
    Lam, K. C.
    Hui, E. K.
    Zee, B.
    BREAST CANCER RESEARCH AND TREATMENT, 2009, 113 (03) : 529 - 535
  • [34] Development of aprepitant, the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting
    Hargreaves, Richard
    Ferreira, Juan Camilo Arjona
    Hughes, David
    Brands, Jos
    Hale, Jeff
    Mattson, Britta
    Mills, Sandy
    PHARMACEUTICAL SCIENCE TO IMPROVE THE HUMAN CONDITION: WINNERS AND FINALIST CANDIDATES OF THE PRIX GALIEN USA, INTERNATIONAL, AND PRO BONO HUMANITARIAN AWARDS 2010, 2011, 1222 : 40 - 48
  • [35] A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy
    Winnie Yeo
    F. K. F. Mo
    J. J. S. Suen
    W. M. Ho
    S. L. Chan
    W. Lau
    J. Koh
    W. K. Yeung
    W. H. Kwan
    K. K. C. Lee
    T. S. K. Mok
    A. N. Y. Poon
    K. C. Lam
    E. K. Hui
    B. Zee
    Breast Cancer Research and Treatment, 2009, 113 : 529 - 535
  • [36] Incidence of chemotherapy-induced nausea and vomiting (CINV) after highly and moderately emetogenic therapy in the era of NK-1 inhibitors - perception versus reality
    Perez-Altozano, J.
    Majem, M.
    Calvo, N.
    Moreno, E.
    Feliu, A.
    Gich, I.
    Mangues, A.
    Barnadas, A.
    EJC SUPPLEMENTS, 2009, 7 (02): : 184 - 184
  • [37] Olanzapine for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): Alliance A221301, a randomized, double-blind, placebo-controlled trial
    Navari, Rudolph M.
    Qin, Rui
    Ruddy, Kathryn Jean
    Liu, Heshan
    Powell, Steven Francis
    Bajaj, Madhuri
    Dietrich, Leah L.
    Lafky, Jacqueline M.
    Loprinzi, Charles L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (29)
  • [38] Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting
    Navari, Rudolph M.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2007, 16 (12) : 1977 - 1985
  • [39] Phase III MAGIC trial of APF530 v ondansetron (Ond) with fosaprepitant (Fos) plus dexamethasone (Dex) for highly emetogenic chemotherapy (HEC)-induced nausea and vomiting: analysis by age and gender.
    Schwartzberg, Lee Steven
    Gabrail, Nashat Y.
    Hrom, John S.
    Vogelzang, Nicholas J.
    Mosier, Michael
    Geller, Robert B.
    Schnadig, Ian
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [40] Cost effectiveness analysis of additional NK-1 receptor antagonist to olanzapine, ondansetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin.
    Mahaparn, Wasamol
    Lertanansit, Chalermchai
    Vinayanuwattikun, Chanida
    Tanasanvimon, Suebpong
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345